FDA Schedules Meeting on Patient-Focused Drug Development for Stimulant Use Disorder

The FDA will hold a March 10 public meeting in Silver Spring, MD., to discuss patient-focused drug development for stimulant use disorder.

The agency is seeking the participation of individuals with the disorder to learn its effects on their health and daily life and the impact of opioid and polysubstance use on their condition, among other topics.

The meeting is part of CDER’s recently announced Controlled Substance Program, which aims to support the development of new policies and programs on access to scheduled drugs.